金河生物(002688) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 527,286,393.92, representing a 1.45% increase compared to CNY 519,765,405.51 in the same period last year[5] - Net profit attributable to shareholders was CNY 36,920,074.20, marking a 16.20% increase from CNY 31,771,635.03 year-on-year[5] - Basic earnings per share rose to CNY 0.0473, up 16.22% from CNY 0.0407 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 527,286,393.92, an increase of 1.0% compared to CNY 519,765,405.51 in Q1 2022[28] - Net profit for Q1 2023 was CNY 40,439,624.37, a decrease of 6.0% from CNY 43,496,662.89 in Q1 2022[29] - The total comprehensive income for the first quarter of 2023 was CNY 34,595,261.09, a decrease from CNY 41,952,788.32 in the previous year, representing a decline of approximately 17.5%[30] Cash Flow - The net cash flow from operating activities decreased by CNY 58,163,894.77, a decline of 158.00% compared to the previous year[15] - The net cash flow from operating activities was negative at CNY -21,352,026.70, compared to a positive CNY 36,811,868.07 in the same period last year[33] - The cash outflow from operating activities totaled CNY 505,294,806.80, compared to CNY 483,337,561.32 in the previous year, an increase of about 4.5%[33] - The company did not report any cash inflow from investment activities, resulting in a net cash flow from investment activities of CNY -60,603,411.71, similar to the previous year's CNY -64,565,989.89[33] - The net cash flow from financing activities was CNY 80,682,022.28, significantly higher than CNY 21,158,538.49 in the previous year, marking an increase of approximately 281.5%[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,573,098,902.44, reflecting a 1.50% increase from CNY 4,505,582,532.92 at the end of the previous year[5] - The company's total liabilities increased to CNY 2,112,802,128.28, up from CNY 2,080,365,862.98 at the beginning of the year[26] - The company's cash and cash equivalents decreased to CNY 421,418,848.00 from CNY 491,367,885.89 at the beginning of the year, representing a decline of 14.2%[24] - The total cash and cash equivalents at the end of the period were CNY 408,318,743.68, down from CNY 492,542,177.26, a decrease of about 17.1%[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 31,495[19] - The largest shareholder, Inner Mongolia Jinhai Holdings Co., Ltd., holds 30.98% of the shares, amounting to 241,758,670 shares[19] - The company plans to implement a restricted stock incentive plan to attract and retain talent, approved by the board on April 21, 2023[22] Operational Metrics - Total operating costs for Q1 2023 were CNY 492,684,043.93, up 3.0% from CNY 477,748,716.72 in the same period last year[28] - Revenue from sales of goods and services received cash of CNY 450,600,293.78, down from CNY 483,989,302.99, indicating a decrease of about 6.5%[32] - Accounts receivable increased to CNY 431,826,292.69, up 5.4% from CNY 409,497,970.35 at the start of the year[24] - Inventory rose to CNY 733,229,854.64, an increase of 8.5% compared to CNY 675,908,511.03 at the beginning of the year[25] - Short-term borrowings increased to CNY 1,270,276,378.56, up 1.9% from CNY 1,246,476,832.69 at the start of the year[26] Other Financial Metrics - The weighted average return on equity increased by 0.36 percentage points to 1.65% compared to 1.29% in the previous year[5] - The company reported a significant increase in interest income, which rose by CNY 1,413,270.37, a 501.81% increase year-on-year[10] - Credit impairment losses increased by CNY 1,571,788.96, representing a 421.29% rise due to extended payment terms from some downstream customers[10] - Other comprehensive income attributable to shareholders decreased by CNY 3,670,579.37, a reduction of 282.29% due to foreign exchange fluctuations[14] - Cash received from investment decreased by ¥30,300,000.00, a decline of 100.00% compared to the previous year, due to the absence of similar business activities[16] - Cash received from other financing activities decreased by ¥1,250,000.00, also a decline of 100.00%, primarily due to the previous year's bank refund of loan deposits[16] - Cash paid for financing activities decreased by ¥70,100,570.65, a reduction of 99.29%, as there were no similar business activities this period[16] - Dividend payments increased by ¥4,713,005.48, an increase of 53.37%, mainly due to the rise in average borrowing amounts[16] - The net effect of exchange rate changes on cash and cash equivalents was an increase of ¥735,386.23, a growth of 35.51% year-on-year[17] - Research and development expenses for Q1 2023 were CNY 15,311,156.03, a decrease of 20.4% from CNY 19,280,982.50 in Q1 2022[29]